Myeloma
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
7 hospitals in India taking patients for this trial.
M S Ramaiah Medical College and HospitalBengaluruDirections ↗
Fortis Memorial Research InstituteGūrgaonDirections ↗
Bhagwan Mahaveer Cancer Hospital & Research CentreJaipurDirections ↗
Nil Ratan Sircar Medical College and HospitalKolkataDirections ↗
Tata Medical CenterKolkataDirections ↗
Rajiv Gandhi Cancer Institute and Research CentreNew DelhiDirections ↗
Deenanath Mangeshkar Hospital and Research CentrePuneDirections ↗
Registry summary (technical)
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Sponsor: Janssen Research & Development, LLC
NCT07518186 on ClinicalTrials.gov
Last updated on the registry 25 Sep 2026 · read by us 20 Oct 2026